The first patient has been dosed with Oxford Biotherapeutic’s (OBT) lead candidate, OBT076, in a Phase 1b trial in adenoid cystic carcinomas (ACC) of the head and neck. This Phase 1b trial is being sponsored by GORTEC – Groupe d’Oncologie Radiothérapie Tête et Cou, an established, internationally renowned European oncology and radiotherapy consortium specializing in head and neck cancer.

The innovative Antibody Drug Conjugate (ADC), with a potential dual mechanism of action, targets the CD205 receptor on both tumor cells as well as certain immune suppressive cells. OBT076 was discovered using OBT’s proprietary OGAP® platform, which is the world’s largest cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets.

Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “The start of this Phase 1b trial investigating our lead asset OBT076 in Adenoid Cystic Carcinoma (ACC) is a major milestone for OBT. We look forward to demonstrating the potential value of OBT076, with the hope to provide meaningful benefit for ACC patients. Additionally, it will contribute to the expanding pool of data affirming the potential of OBT076, both as an ADC monotherapy and as immune primer to boost the effectiveness of CPI immunotherapies, particularly in patients with advanced and/or refractory tumors and those with low PD-L1 expression.”

OBT076 is also currently being evaluated in Phase 1 clinical trials in the US and Europe across several advanced solid tumor indications, including gastric, endometrial, ovarian and non-small cell lung (NSCLC) cancer.